Intensified monitoring with detailed ultrasonography
To learn more about Ro's weight loss offering, visit ro.co/weight-loss/serena
Abstract Purpose of Review Although Glucagon-like peptide (GLP)-1 receptor agonists have been used for almost two decades in the treatment of diabetes mellitus type 2 and, lately, in obesity, recent years have seen an increasing interest in the pharmacological agonism of other proglucagon-derived peptides, including GLP-2
Final Thoughts GLP-1 agonists represent an interesting and evolving area of research in autoimmune care, particularly due to their effects on metabolic health
Start with light weights, focus on learning the movement patterns, and build gradually
Think of the GLP-1 and GIP components as turning down the appetite dial while the glucagon component simultaneously turns up the metabolic furnace